Naturally occurring mutations in the thrombomodulin gene leading to impaired expression and function

被引:48
作者
Kunz, G
Öhlin, AK
Adami, A
Zöller, B
Svensson, P
Lane, DA
机构
[1] Univ London Imperial Coll Sci Technol & Med, Dept Haematol, London W12 0NN, England
[2] Lund Univ, Malmo Univ Hosp, Dept Coagulat Disorders, Malmo, Sweden
[3] Lund Univ, Univ Hosp, Dept Clin Chem, Lund, Sweden
关键词
D O I
10.1182/blood.V99.10.3646
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Sporadic mutations in the thrombomodulin (TM) gene occur in patients with both arterial and venous thrombosis, but the effects of these mutations on expression and function are largely unexplored. Full-length wild-type TM complementary DNA (cDNA) was incorporated into vector pcDNA6 for transfection into COS-7 cells for transient expression. Mutagenesis was performed to create 7 TM mutants with natural mutations either previously identified (Ala25Thr, Gly6lAla, Asp468Tyr, Pro477Ser, Pro483Leu) or reported here (an 11-base pair [bp] deletion, del791-801, leading to STOP306, and a missense mutation, Arg385Ser). Four mutations were found to detrimentally affect the level of expression of the TM protein. Of the missense mutations, 3 had reduced expression compared to wild-type TM (100%), Arg385Ser (50.2% +/- 5%, P < .001), Pro477Ser (76.8% +/-11%, P <.001), Pro483Leu (82.1% +/- 8%, P < .007). No TM protein expression could be detected on the cell surface for mutation del791-801. The cofactor activity of TM in protein C activation was also evaluated. The Michaelis constant (K,) for wild-type thrombin-TM complex was 634 +/- 6 nmol/L. Two mutants, with Arg385Ser and Pro477Ser, had Increased (P < .0001) K, 2967 +/- 283 nM, and 2342 +/- 219 nM, respectively, demonstrating impaired function of the thrombin-TM complex. This work presents biochemical evidence that certain (but not all) natural mutations In the TM gene reduce expression and impair function of the protein on the cell surface, and helps clarify the suggested contribution that these mutations might make to the risk of thromboembolic disease. (C) 2002 by The American Society of Hematology.
引用
收藏
页码:3646 / 3653
页数:8
相关论文
共 58 条
[1]  
Andersen BD, 1996, THROMB HAEMOSTASIS, V76, P143
[2]   TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex [J].
Bajzar, L ;
Morser, J ;
Nesheim, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (28) :16603-16608
[3]   PURIFICATION AND CHARACTERIZATION OF TAFI, A THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR [J].
BAJZAR, L ;
MANUEL, R ;
NESHEIM, ME .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (24) :14477-14484
[4]   Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor [J].
Bajzar, L ;
Nesheim, M ;
Morser, J ;
Tracy, PB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (05) :2792-2798
[5]   Turnover of thrombomodulin at the cell surface occurs at a similar rate to receptors that are not actively internalized [J].
Chu, M ;
Bird, CH ;
Teasdale, M ;
Bird, PI .
THROMBOSIS AND HAEMOSTASIS, 1998, 80 (01) :119-127
[6]  
CLARKE JH, 1993, J BIOL CHEM, V268, P6309
[7]   The amino terminal lectin-like domain of thrombomodulin is required for constitutive endocytosis [J].
Conway, EM ;
Pollefeyt, S ;
Collen, D ;
SteinerMosonyi, M .
BLOOD, 1997, 89 (02) :652-661
[8]   AN ULTRASTRUCTURAL-STUDY OF THROMBOMODULIN ENDOCYTOSIS - INTERNALIZATION OCCURS VIA CLATHRIN-COATED AND NON-COATED PITS [J].
CONWAY, EM ;
BOFFA, MC ;
NOWAKOWSKI, B ;
STEINERMOSONYI, M .
JOURNAL OF CELLULAR PHYSIOLOGY, 1992, 151 (03) :604-612
[9]  
DAHLBACK B, 1994, MOL BASIS BLOOD DISE, P599
[10]  
Doggen CJM, 1998, THROMB HAEMOSTASIS, V80, P743